IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Alembic Completes Acquisition of Dabur Pharma

1:44 PM MDT | April 25, 2007 | DR

Pharmaceutical company Alembic (Vadodara, India) says it has completed the acquisition of the non-oncology formulation business of Dabur Pharma (New Delhi) for approximately $37 million. Alembic acquired full rights to market 24 Dabur brands, under the terms of the deal. Most of the brands are in the high-growth lifestyle therapeutic segments of cardiology, diabetology, and gynecology. Alembic is the largest player in the anti-infective drug segment in India, and aims to increase market share in the lifestyle segment. “With this acquisition, we have a ready...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa